Saama has expanded its multi-year agreement with Pfizer to integrate artificial intelligence (AI)-based data solutions across the latter’s research and development (R&D) portfolio.

Based in California, Saama provides AI-based solutions that expedite the clinical development and commercialisation processes.

The deal expands the strategic alliance that started in 2020 when both firms teamed up to use AI to automate Pfizer’s data review procedures.

The outcome of that early collaboration, Smart Data Quality (SDQ), is said to reduce the time to database lock.

Under the terms of the new agreement, Pfizer will keep scaling SDQ to help expedite and simplify its data review procedures throughout its larger portfolio of international research.

Saama chief technology officer and chief product officer Lisa Moneymaker said: “Our initial collaboration with Pfizer for its Covid-19 vaccine demonstrated the unprecedented power of our AI-enabled technology platform to improve and accelerate the clinical trial process, and ultimately, its ability to help bring treatments to patients faster.

“The opportunity to now scale across more of the Pfizer portfolio underscores the evidence-based potential of Saama’s one-of-a-kind platform to fundamentally change the way drug development is done to benefit more people around the world.”

The new deal broadens the partnership beyond SDQ to support Pfizer in fast tracking regulatory filings throughout its portfolio by utilising Saama’s advanced Biometrics Research and Analysis Information Network.

The solution is said to digitise study specifications, streamline statistical programming and biostatistics workflows, and creates submission-ready tables, listings, and figures (TLF) artifacts. These give the American pharmaceutical firm the potential to shorten regulatory submission timelines across its global portfolio.

Additionally, the solution will help lay the groundwork for future trial submissions to be even faster through ongoing automation and innovation.

Saama’s solutions provide research teams with the ability to handle the large volume and diversity of clinical trial data that is available today by utilising the most advanced technology and AI capabilities.

Pfizer vice president and data monitoring and management global head Demetris Zambas said: “We look forward to expanding our strategic partnership with Saama across our global portfolio, leveraging their cutting-edge, AI-based technologies to reduce the time and effort required for data review and reconciliation, and to improve the quality and consistency of data across routine and complex clinical studies alike.”